The world of giant viruses was brutally opened up at the beginning of the 21st century when a microorganism visible under the microscope, Gram stained, and which had been considered a bacterium for several years, was identified as the largest virus known at the time: it was Mimivirus [1,2]. Its genome contained more than 1,200 genes and had the particularity, given the wealth of information it contained, to harbor genes common to bacteria, archaea and eukaryotes [3]. To me, this particular feature was the most striking, and I postulated immediately for the publication of the genome, believing that this virus might be representative of a fourth domain [3]. This caused various reactions, in spite of a subsequent classification into four branches using genes encoding for RNA polymerase showing four groups: giant viruses, archaea, bacteria and eukaryotes [4,5]. For a while, I was the only one to believe in the existence of a fourth domain, which was challenged both by Jean-Michel Claverie and C.E. Woese [6]. We proposed later, based on these data, to create a new classification splitting organisms into capsid-encoding organisms and ribosome-encoding organisms [7]. In this issue, the specificity of codon and amino acid use of this group of viruses is reported [8].

Since then, we have reported the existence of a new family of viruses, Marseilleviridae [9], the first strain being Marseillevirus [10]. The recent discovery of a new giant virus, considered to be an intracellular eukaryotic parasite for 15 years [11], shows that the world of giant viruses keeps expanding and challenges the traditional classification of microbes [2]. As a matter of fact, in the 20th century, some giant viruses were considered for a long time to be bacteria or parasites because the size factor biased their initial viral classification. Indeed, the established definition of a virus during the 20th century considered that all viruses should have at least one dimension of less than 0.2 μm [2,7]. Giant viruses pose a problem to traditional virology techniques because purification techniques prior to virome study involve a filtration that removes giant viruses [12,13,14]. We were recently able to show that, when avoiding 0.2-μm filtration, giant viruses belonging to the Marseillevirus family could be found circulating in the blood of asymptomatic patients [13,14]. In addition, for now, PCR techniques have unfortunately demonstrated little sensitivity because, due to the high variability of these viruses, tools were lacking to identify them [2,15]. Culture techniques have indeed enabled the isolation of these viruses for the first time in human stool samples, with a reference reported in this paper [16]. New strategies for culture, purification [17] and isolation techniques [16] are reported in the present issue. Also, for the first time, these techniques have enabled the isolation of Mimivirus from a respiratory sample [18,19] and the stools of a patient with pneumonia [20]. However, it is likely that serology is more effective in the detection of specific antibodies against the Marseilleviridae family, as related in Gilbert Greub's work in this journal [21].

These data confirm that both Mimiviridae and Marseilleviridae may be found in humans [19]. Mimivirus seems to be linked to pneumonia and Marseillevirus is associated with asymptomatic carriage into blood [13] or in feces [22]. A case of adenitis in a young child has been identified [14] and antibodies to this virus have been found in blood donors [13,21].

Finally, it is possible to find these viruses in many environmental samples, in sea and soil [16], and also in insects [23]. A large part of the viral world likely eluded us due to a definition problem related to the size of these viruses. In one paper of this issue, I propose abandoning the term domain (used to define living organisms based on the ribosome), which divided the microbial world into three after the prokaryote/eukaryote dichotomy in the 20th century and the definition of microbes as a sole entity in the 19th century [2]. My proposal, TRUC, which offers a classification into four branches, is probably transitory and will most likely have to be modified over time as our knowledge of the microbial world increases.

In conclusion, this issue of Intervirology makes it possible to understand that the knowledge of viruses in the 21st century challenges our existing approach by integrating viruses such as microorganisms likely to be themselves infected by other viruses, virophages able to regulate their growth [24,25] and, finally, viruses and virophages that can be infected themselves by selfish genes, polintons and transpovirons [25,26] which act as gene vehicles from one organism to another. We are at the beginning of a great revolution in virology and this issue of Intervirology may contribute to the further discovery of giant viruses that are as yet an unknown.

1.
La Scola B, Audic S, Robert C, Jungang L, de Lamballerie X, Drancourt M, Birtles R, Claverie JM, Raoult D: A giant virus in amoebae. Science 2003;299:2033.
2.
Raoult D: TRUC or the need for a new microbial classification. Intervirology 2013;56:349- 353.
3.
Raoult D, Audic S, Robert C, Abergel C, Renesto P, Ogata H, La Scola B, Suzan M, Claverie JM: The 1.2-megabase genome sequence of Mimivirus. Science 2004;306:1344-1350.
4.
Boyer M, Madoui MA, Gimenez G, La Scola B, Raoult D: Phylogenetic and phyletic studies of informational genes in genomes highlight existence of a 4th domain of life including giant viruses. PLoS One 2010;5:e15530.
5.
Colson P, de Lamballerie X, Fournous G, Raoult D: Reclassification of giant viruses composing a fourth domain of life in the new order Megavirales. Intervirology 2012;55:321-332.
6.
Zakaib GD: The challenge of microbial diversity: out on a limb. Nature 2011;476:20-21.
7.
Raoult D, Forterre P: Redefining viruses: lessons from Mimivirus. Nat Rev Microbiol 2008;6:315-319.
8.
Colson P, Fournous G, Diene SM, Raoult D: Codon usage, amino acid usage, transfer RNA and amino-acyl-tRNA synthetases in mimiviruses. Intervirology 2013;56:364-375.
9.
Colson P, Pagnier I, Yoosuf N, Fournous G, La Scola B, Raoult D: ‘Marseilleviridae', a new family of giant viruses infecting amoebae. Arch Virol 2013;158:915-920.
10.
Boyer M, Yutin N, Pagnier I, Barrassi L, Fournous G, Espinosa L, Robert C, Azza S, Sun S, Rossmann MG, Suzan-Monti M, La SB, Koonin EV, Raoult D: Giant Marseillevirus highlights the role of amoebae as a melting pot in emergence of chimeric microorganisms. Proc Natl Acad Sci USA 2009;106:21848-21853.
11.
Philippe N, LeGendre M, Doutre G, Coute Y, Poirot O, Lescot M, Arslan D, Seltzer V, Bertaux L, Bruley C, Garin J, Claverie JM, Abergel C: Pandoraviruses: amoeba viruses with genomes up to 2.5 Mb reaching that of parasitic eukaryotes. Science 2013;341:281-286.
12.
Colson P, Fancello L, Gimenez G, Armougom F, Desnues C, Fournous G, Yoosuf N, Million M, La Scola B, Raoult D: Evidence of the megavirome in humans. J Clin Virol 2013;57:191-200.
13.
Popgeorgiev N, Boyer M, Fancello L, Monteil S, Robert C, Rivet R, Nappez C, Azza S, Chiaroni J, Raoult D, Desnues C: Marseillevirus-like virus recovered from blood donated by asymptomatic humans. J Infect Dis 2013, E-pub ahead of print.
14.
Popgeorgiev N, Temmam S, Raoult D, Desnues C: Describing the silent human virome with an emphasis on giant viruses. Intervirology 2013;56:395-412.
15.
Ngounga T, Pagnier I, Reteno D-G I, Raoult D, La Scola B, Colson P: Real-time PCR systems targeting giant viruses of amoebae and their virophages. Intervirology 2013;56:413-423.
16.
Pagnier I, Reteno D-G I, Saadi H, Boughalmi M, Gaia M, Slimani M, Ngounga T, Belkiz M, Raoult D, La Scola B: A decade of improvements in Mimiviridae and Marseilleviridae isolation from amoeba. Intervirology 2013;56:354-363.
17.
Slimani M, Pagnier I, Boughalmi M, Raoult D, La Scola B: Alcohol disinfection procedure for isolating giant viruses from contaminated samples. Intervirology 2013;56:434-440.
18.
Saadi H, Pagnier I, Colson P, Cherif JK, Beji M, Boughalmi M, Azza S, Armstrong N, Robert C, Fournous G, La Scola B, Raoult D: First isolation of Mimivirus in a patient with pneumonia. Clin Infect Dis 2013;57:e127-e134.
19.
Colson P, La Scola B, Raoult D: Giant viruses of amoebae as potential human pathogens. Intervirology 2013;56:376-385.
20.
Saadi H, Reteno D-GI, Colson P, Aherfi S, Minodier P, Pagnier I, Raoult D, La Scola B: Shan virus: a new Mimivirus isolated from the stool of a Tunisian patient with pneumonia. Intervirology 2013;56:424-429.
21.
Mueller L, Baud D, Bertelli C, Greub G.: Lausannevirus seroprevalence among asymptomatic young adults. Intervirology 2013;56:430-433.
22.
Lagier JC, Armougom F, Million M, Hugon P, Pagnier I, Robert C, Bittar F, Fournous G, Gimenez G, Maraninchi M, Trape JF, Koonin EV, La Scola B, Raoult D: Microbial culturomics: paradigm shift in the human gut microbiome study. Clin Microbiol Infect 2012;18:1185-1193.
23.
Boughalmi M, Pagnier I, Aherfi S, Colson P, Raoult D, La Scola B: First Isolation of a Marseillevirus in the Diptera Syphidae Eristalis tenax. Intervirology 2013;56:386-394.
24.
La Scola B, Desnues C, Pagnier I, Robert C, Barrassi L, Fournous G, Merchat M, Suzan-Monti M, Forterre P, Koonin E, Raoult D: The virophage as a unique parasite of the giant Mimivirus. Nature 2008;455:100-104.
25.
Desnues C, La Scola B, Yutin N, Fournous G, Robert C, Azza S, Jardot P, Monteil S, Campocasso A, Koonin EV, Raoult D: Provirophages and transpovirons as the diverse mobilome of giant viruses. Proc Natl Acad Sci USA 2012;109:18078-18083.
26.
Yutin N, Raoult D, Koonin EV: Virophages, polintons, and transpovirons: a complex evolutionary network of diverse selfish genetic elements with different reproduction strategies. Virol J 2013;10:158.
Open Access License / Drug Dosage / Disclaimer
Open Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.